P‐glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF‐β signaling pathway inhibitor galunisertib
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
P‐glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF‐β signaling pathway inhibitor galunisertib
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-07-15
DOI
10.1002/ijc.32568
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study
- (2019) M.M. Tibben et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib
- (2018) Wenlong Li et al. INTERNATIONAL JOURNAL OF CANCER
- Discovery of a drug candidate for GLIS3-associated diabetes
- (2018) Sadaf Amin et al. Nature Communications
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- P-glycoprotein and Breast Cancer Resistance Protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability
- (2018) Wenlong Li et al. PHARMACOLOGICAL RESEARCH
- Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics
- (2017) Kenneth C. Cassidy et al. XENOBIOTICA
- A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
- (2015) G. Giaccone et al. EUROPEAN JOURNAL OF CANCER
- A Novel Preclinical Method to Quantitatively Evaluate Early-Stage Metastatic Events at the Murine Blood-Brain Barrier
- (2014) C. E. Adkins et al. Cancer Prevention Research
- First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
- (2014) Jordi Rodon et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
- (2014) Jordi Rodón et al. INVESTIGATIONAL NEW DRUGS
- Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent
- (2014) Cheng Hua Jin et al. JOURNAL OF MEDICINAL CHEMISTRY
- What do drug transporters really do?
- (2014) Sanjay K. Nigam NATURE REVIEWS DRUG DISCOVERY
- Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
- (2014) John C. Morris et al. PLoS One
- Targeting the TGFβ signalling pathway in disease
- (2012) Rosemary J. Akhurst et al. NATURE REVIEWS DRUG DISCOVERY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The Antisense Oligonucleotide Trabedersen (AP 12009) for the Targeted Inhibition of TGF-β2
- (2011) Frank Jaschinski et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Anti-Transforming Growth Factor Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells
- (2010) Z. Zhong et al. CLINICAL CANCER RESEARCH
- Organic anion transporting polypeptide 1a/1b–knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs
- (2010) Evita van de Steeg et al. JOURNAL OF CLINICAL INVESTIGATION
- Cytochrome P450-mediated metabolism in the human gut wall
- (2010) Kirstin Thelen et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice
- (2007) Lorea Bueno et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search